Latest Conference Articles

March 31st 2016, 3:13pm

NCCN Annual Conference

The NCCN's Evidence Blocks need further data and refinement to overcome subtleties of distinction in drug performance, but they’re the best value system developed so far, NCCN officials reported at their 2016 Annual Conference.

March 31st 2016, 2:06pm

NCCN Annual Conference

Andrew D. Zelenetz, MD, PhD, medical director, Quality Informatics, Memorial Sloan Kettering Cancer Center, discusses the role of biosimilars in cancer care. Zelenetz spoke about this topic at the 2016 NCCN Annual Conference.

March 31st 2016, 1:14pm

NCCN Annual Conference

Anne Covey, MD, interventional radiologist, Memorial Sloan Kettering Cancer Center, discusses recent and future changes to locoregional treatment approaches for hepatocellular carcinoma (HCC).

March 31st 2016, 1:02pm

NCCN Annual Conference

The 2016 NCCN Annual Conference included a push to find more effective ways to encourage and deliver palliative care services across a variety of settings in oncology.

March 31st 2016, 12:00pm

NCCN Annual Conference

Alan P. Venook, MD, shares insight into the evolving treatment paradigm for colorectal cancer.

March 22nd 2016, 1:02pm

SGO Annual Meeting

Weekly paclitaxel for recurrent ovarian cancer prevailed over the VEGF inhibitor cabozantinib in a randomized comparison of the two drugs.

March 22nd 2016, 12:42pm

SGO Annual Meeting

Three different chemotherapy regimens, each combined with bevacizumab, failed to demonstrate an advantage for patients with advanced ovarian cancer or build on results of a landmark trial reported more than a decade ago.

March 22nd 2016, 10:46am

SGO Annual Meeting

Ursula A. Matulonis, MD, discusses ongoing developments with olaparib, as well as the overall future of PARP inhibitors in ovarian cancer.

March 21st 2016, 2:23pm

SGO Annual Meeting

Jean Hurteau, MD, professor, Division of Gynecologic Oncology at NorthShore University Health System, discusses the difficulties of diagnosing ovarian clear cell carcinoma. Hurteau says data for the diagnosis of the carcinoma is older, and is not relevant to contemporary diagnoses due to the fact that there were more mixed tumors previously than there are now.

March 21st 2016, 2:20pm

SGO Annual Meeting

Bobbie J. Rimel, MD, assistant professor, Obstetrics and Gynecology, discusses discovering BRCA mutations early in ovarian cancer patients. Rimel says with the genetic information of knowing which patients harbor which genetic mutations, oncologists can offer their patients treatments such as PARP inhibitors, which are gene-specific.

March 21st 2016, 1:01pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

John Byrd, MD, director of the Division of Hematology, Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, discusses the RESONATE 2 study, which looked at ibrutinib versus chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia (CLL).

March 21st 2016, 12:47pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Sundar Jagannath, MD, professor of Medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses upcoming agents in multiple myeloma.

March 21st 2016, 11:41am

SGO Annual Meeting

An ongoing clinical trial has begun the process of evaluating whether the addition of a booster agent can take the anticancer activity of PD-1 directed immunotherapy to another level.

March 21st 2016, 9:47am

SGO Annual Meeting

Shannon Westin, MD, discusses refining the use of PARP inhibitors in ovarian cancer by gaining a greater understanding of mechanisms of resistance and exploring combination and sequencing possibilities.

March 21st 2016, 9:35am

SGO Annual Meeting

An investigational extended-release formulation of the antiemetic granisetron achieved a complete response more often than did ondansetron in cancer patients receiving highly emetogenic cisplatin-based chemotherapy.

March 21st 2016, 6:07am

SGO Annual Meeting

Terri Febbraro, MD, third year fellow, University of Chicago/NorthShore University Health System, discusses length of time receiving chemotherapy versus overall survival in patients with ovarian cancer. Febbraro says the study looked at three separate groups of patients with ovarian cancer based on the length of time they receieved chemotherapy, with the group being on chemotherapy the longest having the worst overall survival rates.

March 21st 2016, 6:04am

SGO Annual Meeting

Martee Hensley, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the introduction of trabectedin into the armamentarium for uterine leiomyosarcoma. Hensley says the FDA approval for the treatment requires patients to have had a prior anthracycline therapy, and the treatment will likely fall into the third- or fourth-line of treatment for the malignancy. She adds that trabectedin may fall into the fourth-line due to treatments such as pazopanib currently occupying the third-line.

March 20th 2016, 11:52am

SGO Annual Meeting

Treatment with trabectedin significantly improved progression-free survival compared with dacarbazine in women with advanced uterine leiomyosarcoma, according to a subgroup analysis of the phase III SAR-3007 trial.

March 20th 2016, 11:47am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Targeted agents, particularly ibrutinib and idelalisib, are becoming increasingly important in the treatment of chronic lymphocytic leukemia, and have replaced chemotherapy in many settings.

March 20th 2016, 10:55am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Chimeric antigen receptor-modified T-cell therapies have demonstrated durable complete responses for patients with relapsed/refractory B-cell acute lymphoblastic leukemia; however, several questions remain regarding their optimal use and applicability outside of this disease.